Trial reportThe American journal of gastroenterology2018
A Randomized Double-Blind, Placebo-Controlled, Cross-Over Study Using Baclofen in the Treatment of Rumination Syndrome.
Trial report in The American journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- European Guideline on Chronic Nausea and Vomiting-A UEG and ESNM Consensus for Clinical Management.United European gastroenterology journal · 2025Guideline
- Baclofen as a therapeutic option for gastroesophageal reflux disease: A systematic review of clinical trials.Frontiers in medicine · 2023Pooled it
- The rumination severity index: Development and evaluation of a scoring tool for rumination syndrome.Journal of pediatric gastroenterology and nutrition · 2026Article
- Diagnostic and Management Review of Gastric and Supragastric Belching, Aerophagia, and Rumination Syndrome.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026Review
- Approved and Pipeline Pharmacological Interventions for Eating Disorders (2010-2025): 15 Years of Progress (or Lack Thereof).CNS drugs · 2026Review
- Therapeutic Efficacy of Flupentixol-Melitracen for Treatment of Aerophagia in Adults: A Single-Center Parallel Randomized Controlled Trial.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Rumination Syndrome, Supragastric Belching, and Abdominophrenic Dyssynergia: How to Diagnose and Treat?Current gastroenterology reports · 2025Review
- Laryngopharyngeal reflux disease: Updated examination of mechanisms, pathophysiology, treatment, and association with gastroesophageal reflux disease.World journal of gastroenterology · 2024Review
- A Retrospective Review of Baclofen Treatment for Children with Rumination Syndrome at a Single Center.Paediatric drugs · 2023Article
- Rumination syndrome: pathophysiology, diagnosis and practical management.Frontline gastroenterology · 2022Article
- Prevalence, symptoms and risk factor profile of rumination syndrome and functional dyspepsia: a population-based study.Alimentary pharmacology & therapeutics · 2021Article
- Chicago classification version 4.0Neurogastroenterology and motility · 2021Review
- Rumination Syndrome in Children and Adolescents: A Mini Review.Frontiers in pediatrics · 2021Review
- High-Resolution Manometry-Observations After 15 Years of Personal Use-Has Advancement Reached a Plateau?Current gastroenterology reports · 2020Review
- Non-acid Reflux: When It Matters and Approach to Management.Current gastroenterology reports · 2020Review
- Phenotypes of Gastroesophageal Reflux Disease: Where Rome, Lyon, and Montreal Meet.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020Review
- Personalized Approach in the Work-up and Management of Gastroesophageal Reflux Disease.Gastrointestinal endoscopy clinics of North America · 2020Review
- Chronic Burping and Belching.Current treatment options in gastroenterology · 2020Review
- Rumination Syndrome: Recognition and Treatment.Current treatment options in gastroenterology · 2020Review
- Diagnosis and Treatment of Rumination Syndrome: A Critical Review.The American journal of gastroenterology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesBoth rumination syndrome and supra-gastric belching (SGB) have limited treatment options. We demonstrated (open-label) that baclofen reduces pressure flow events in these patients. We aimed to study the effect of baclofen in a placebo-controlled, double-blind, cross-over study in patients with clinically suspected rumination and/or SGB.
methodsTwenty tertiary-care patients (mean age 42 years (range 18-61), 13f) with clinically suspected rumination and/or SGB were randomized to receive baclofen (10 mg, t.i.d) or placebo for 2 weeks with cross-over to the alternative intervention after a 1 week wash-out period. At the end of each treatment period, patients underwent a solid-state high-resolution impedance manometry measurement, during which they registered symptoms. Patients received a solid meal and recordings continued for 1 h. They scored overall treatment evaluation (OTE) on a -3 to +3 scale.
resultsBoth the number of regurgitation event markers and rumination episodes were significantly decreased after baclofen (6 (0-19) vs. 4 (0-14), P=0.04; 13 (8-22) vs. 8 (3-11), P=0.004). The number of SGB episodes was similar in both groups. Lower esophageal sphincter (LES) pressure was significantly higher and the number of transient LES relaxations was significantly lower after baclofen (17.8 (12.7-22.7) vs. 13.1 (7.2-16.9) mm Hg, P=0.0002; 4(1-8) vs. 7(3-12), P=0.17). The number of reflux events decreased in the baclofen condition (4 (1-9) vs. 3 (0-6), P=0.03). Straining episodes were similar in both arms, but the rumination/straining ratio was significantly lower in the baclofen arm (0.06 (0-0.32) vs. 0.33 (0-0.51), P=0.0012). OTE was superior after baclofen compared to placebo (P=0.03).
conclusionsBaclofen is an effective treatment option for patients with rumination syndrome, probably through its effect on LES pressure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.